Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF combined with leucogen for myelosuppression after autologous HSCT
ChiCTR2500103184Phase 4Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- May 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of filgrastim in myelosuppression (2 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Neutrophil engraftment time. Planned start May 2025; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
myelosuppression
Beyond the preview
Go deeper on ChiCTR2500103184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103184.